The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).
Adrienne Alise Phillips
No relevant relationships to disclose
Paul Fields
No relevant relationships to disclose
Olivier Hermine
No relevant relationships to disclose
Graham Taylor
No relevant relationships to disclose
Maria L. Delioukina
No relevant relationships to disclose
Steven M. Horwitz
Research Funding - Kyowa Hakko Kirin
Juan Carlos Ramos
Research Funding - Kyowa Hakko Kirin
Jean Côme Meniane
No relevant relationships to disclose
Stefan K. Barta
No relevant relationships to disclose
Karen M. Dwyer
Employment or Leadership Position - Kyowa Hakko Kirin
Michael R. Kurman
Consultant or Advisory Role - Kyowa Hakko Kirin
Andrew Saunders
Consultant or Advisory Role - Kyowa Hakko Kirin
Dmitri O. Grebennik
Employment or Leadership Position - Kyowa Hakko Kirin
Kevin Conlon
Research Funding - CRADA contract funding